The 2019 Worldwide Market for Cancer Immunotherapy - Focus on Pharmaceutical Products & Therapeutic Indication (2018-2028): A $170+ Billion Opportunity -

DUBLIN--()--The "Global Cancer Immunotherapy Market: Focus on Pharmaceutical Products, Therapeutic Indication, Competitive Landscape and Region - Analysis and Forecast, 2018-2028" report has been added to's offering.

According to WHO, cancer claimed 8.8 million lives in 2015 and accounted for almost 1 in 6 global deaths. In low- and middle-income countries, about 70% of deaths are caused due to cancer, resulting in a significant burden on the healthcare and economy of these countries. The treatment of cancer is long-term and involves extensive therapies that are expensive, and act as an economic burden on the patients and their families. It has been estimated that global spending on cancer therapies and supportive care drugs exceed $133 billion and is expected to increase to $200 billion by 2022.

Cancer Immunotherapy or, immuno-oncology, is the treatment that utilizes the body's self-immune system to combat cancer. The immunotherapy treatments either boost the body's immune system against cancer or acts as the immune system to identify the cancerous cells and destroy them. Immunotherapy is precision (personalized) medicine that works better for some types of cancer; however, this treatment is now used for different types of cancer. The first immunotherapy treatment, Yervoy, was approved and commercialized in 2011 by US-based bio-pharmaceutical company, Bristol-Myers Squibb.

Recently with the discovery of new oncology targets and increased knowledge about cancer, newer immunotherapy options have been discovered. For e.g., approval of novel checkpoints (targets in the body of a patient with cancer) inhibitors against PD-1 and PD-L1, have revolutionized the immune-oncology market with their rapid uptake among the patients.

The global cancer immunotherapy market was valued at $39.86 billion in 2017 and is anticipated to reach $170.7 billion by 2028.

The rising prevalence of cancer around the world and high unmet medical needs of patients with cancer are stimulators for the growth of the cancer immunotherapy market. In addition, the advancements in precision medicine for immuno-oncology and rise in expenditure by pharmaceutical companies on R&D for cancer treatments, are contributing to the rise in demand for cancer immunotherapy as a treatment for cancer.

Based on products, the market can be sub-segmented into monoclonal antibodies, check point inhibitors, cancer vaccine, and others. The market for monoclonal antibodies dominates the market in terms of revenue. The growth of the monoclonal antibodies market is accredited to the efficacy of these targeted antibodies, rising demand for advanced oncology medicines along with an increase in the research and development facilities globally. However, Check Point Inhibitors exhibit a higher growth rate as they have shown to be more efficacious and have less toxicity as compared to other product classes. These products have a novel mechanism of action which have revolutionized the cancer immunotherapy market.

Based on therapeutic indication, the market can be classified into seven major cancer types, which include breast cancer, melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, renal cell carcinoma, gastric cancer, and others. Among the different types of cancers, breast cancer is the leading contributor to metastatic cancer treatment market, while the highest CAGR is expected to be registered by NSCLC during the forecast period from 2018 to 2028.

The cancer immunotherapy market has a promising potential for growth in the coming years. The report provides an in-depth SWOT analysis of different key players of the market, supported by an extensive financial summary of each company. The key players of the market are Aduro Biotech, Inc, Amgen Inc., AstraZeneca PLC, Boehringer Ingelheim, Bristol Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Gilead Sciences, Inc, among others.

Topics Covered

Executive Summary

1 Market Overview
1.1 Cancer Immunotherapy
1.2 Types of Cancer Immunotherapy

2 Market Dynamics
2.1 Drivers
2.1.1 Rising Prevalence of Cancer
2.1.2 Unmet Medical Needs of Cancer Patients
2.1.3 Rising R&D Expenditure in the Immuno-Oncology Segment
2.1.4 Advancement of Precision Medicine in Immuno-oncology
2.2 Restraints
2.2.1 High Cost of Treatment
2.2.2 Adverse Effects of Immunotherapy Treatment
2.3 Opportunities
2.3.1 Development of Targeted Therapy
2.3.2 Development of Healthcare Infrastructure and Reimbursement Policies in Emerging Economies
2.3.3 Combination Therapy

3 Competitive Landscape
3.1 Key Developmental Strategies
3.2 Market Share Analysis

4 Industry Insights
4.1 Regulatory Organizations/ Associations/ Consortiums
4.2 Patent Landscape
4.3 Regulatory Designations

5 Global Cancer Immunotherapy Market (By Product)
5.1 Monoclonal Antibodies
5.2 Checkpoint Inhibitors
5.3 Cancer Vaccines

6 Global Cancer Immunotherapy Market (by Therapeutic Indication)
6.1 Breast Cancer
6.2 Non-Small Cell Lung Cancer (NSCLC)
6.3 Melanoma
6.4 Colorectal Cancer
6.5 Renal Cell Carcinoma
6.6 Gastric Cancer
6.7 Others

7 Global Cancer Immunotherapy Market (by Region)
7.1 North America
7.2 Europe
7.3 Asia-Pacific
7.4 Latin America
7.5 Rest-of-the-World (RoW)

8 Company Profiles
8.1 Overview
8.2 Aduro Biotech
8.3 Amgen
8.4 AstraZeneca PLC
8.5 Bristol-Myers Squibb
8.6 Celgene Corporation
8.7 DNAtrix Therapeutics
8.8 Eli Lilly and Company
8.9 Gilead Sciences Inc.
8.10 Fate Therapeutics
8.11 F. Hoffmann La Roche
8.12 Johnson & Johnson
8.13 Merck & Co. Inc.
8.14 Novartis AG
8.15 Pfizer Inc.
8.16 Precision BioSciences Inc.
8.17 Iovance Biotherapeutics: Snapshot

9 Research Scope and Methodology
9.1 Scope of the Report
9.2 Global Cancer Immunotherapy Market Segmentation
9.3 Research Methodology
9.4 Assumptions and Limitations

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs